NICE has made a series of recommendations in technology appraisals for new drugs.
Rituximab in combination with methotrexate has been recommended as an option for the treatment of refractory rheumatoid arthritis.
But NICE said rituximab and methotrexate should only be used if other disease modifying anti-rheumatic drugs have not worked, and there is an adequate response to it.
Repeat courses should only be given every six months and all courses should be monitored by specialists, the institute ruled.
Adalimumab has also been approved for treatment of moderate to severe psoriatic arthritis and natalizumab has been recommended for treating highly active relapsing-remitting multiple sclerosis.
NICE, however, recommended againstpemetrexed for non small-cell lung cancer.